SI-BONE, Inc. SIBN

Company Overview

SI-BONE, Inc. is a publicly traded medical device company focused on developing and commercializing minimally invasive surgical solutions for the treatment of disorders of the sacroiliac (SI) joint. The company operates within the orthopedic and spine medical device industry, with a primary emphasis on addressing chronic low back pain attributed to SI joint dysfunction, a condition historically underdiagnosed and undertreated.

The company’s core revenue driver is its proprietary iFuse Implant System®, which is designed to stabilize and fuse the SI joint using a minimally invasive approach. SI-BONE primarily serves orthopedic surgeons, neurosurgeons, and spine surgeons, with procedures reimbursed largely through established hospital and outpatient care pathways. Founded in 2008, the company was among the first to focus exclusively on SI joint fusion, positioning itself as a category pioneer with extensive clinical evidence supporting its products. SI-BONE completed its initial public offering in 2018 and has since focused on expanding clinical adoption and procedural awareness.